Scott Solomon, M.D.

Scott Solomon, M.D., is board certified in the subspecialties of medical oncology and hematology. He is Medical Director of the Northside Hospital Blood and Marrow Transplant Matched Unrelated Donor Program and Medical Director of the Northside Hospital Stem Cell Processing Laboratory. Dr. Solomon is also a Northside Hospital Leukemia Program physician. In 2016 – 2022, Dr. Solomon was recognized as among Atlanta’s Top Doctors in his specialty by Castle Connolly.


  • University of Virginia, Echols Scholar and a member of Phi Beta Kappa Honor Society
  • M.D., Alpha Omega Alpha Honor Society, University of Maryland School of Medicine
    • Participated in highly competitive Howard Hughes Medical Institute (HHMI)- NIH Research Scholars Program
    • Received the Medical Student Research Award from the American Federation for Clinical Research
  • Fellowship in Hematology/Oncology, University of California, San Francisco

Society Memberships

  • American Society of Clinical Oncology
  • American Society of Hematology
  • American Society for Blood and Marrow Transplantation

Past Academic Faculty Appointments

  • National Institutes of Health (NIH), National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland


  • Authored and co-authored more than 215 research articles and abstracts in peer-reviewed journals; Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, the British Journal of Hematology

Dr. Solomon’s clinical and translational research interests include novel approaches to treating leukemia, lymphoma, and myeloma. More specifically, his work has focused on the role of allogeneic and autologous immune system modulation to treat various blood cancers. Past and current trials evaluate the role of haploidentical transplantation, CAR-T therapy, immune checkpoint inhibitors and adoptive immunotherapy. In addition, another clinical interest involves improving the success of allogeneic stem cell transplantation, with an emphasis on developing novel graft-versus-host disease (GVHD) prevention and treatment strategies.